Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Higgins

Showing results (261-270 of 283) with videos related to

Pageof 29
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 28, 2021
Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control StudyJeffrey A Berinstein, Jessica L Sheehan, Michael Dias, et al.
Inflammatory Bowel Diseases|December 6, 2021
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVIDKimberly N Weaver, Xian Zhang, Xiangfeng Dai, et al.
Gut|May 19, 2012
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trialWolfgang Hueber, Bruce E Sands, Steve Lewitzky, et al.
Nature Medicine|February 19, 2020
Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiotaHiroko Nagao-Kitamoto, Jhansi L Leslie, Sho Kitamoto, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 16, 2024
Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and EndpointsSailish Honap, Vipul Jairath, Bruce E Sands, et al.
Lancet (London, England)|June 1, 2022
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trialsSilvio Danese, Séverine Vermeire, Wen Zhou, et al.
Gastroenterology|April 12, 2022
Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal SurgeryBenjamin L Cohen, Phillip Fleshner, Sunanda V Kane, et al.
The American Journal of Gastroenterology|January 14, 2022
Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel DiseasesMichael D Kappelman, Kimberly N Weaver, Xian Zhang, et al.
Alimentary Pharmacology & Therapeutics|November 10, 2015
Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammationA J F Coimbra, J Rimola, S O'Byrne, et al.
Journal of Pediatric Gastroenterology and Nutrition|February 15, 2024
Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel diseaseArthur J Kastl, Kimberly N Weaver, Xian Zhang, et al.
Pageof 29

Showing results (261-270 of 283) with videos related to

Sort By:
Pageof 29
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 28, 2021
Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control StudyJeffrey A Berinstein, Jessica L Sheehan, Michael Dias, et al.
Inflammatory Bowel Diseases|December 6, 2021
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVIDKimberly N Weaver, Xian Zhang, Xiangfeng Dai, et al.
Gut|May 19, 2012
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trialWolfgang Hueber, Bruce E Sands, Steve Lewitzky, et al.
Nature Medicine|February 19, 2020
Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiotaHiroko Nagao-Kitamoto, Jhansi L Leslie, Sho Kitamoto, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 16, 2024
Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and EndpointsSailish Honap, Vipul Jairath, Bruce E Sands, et al.
Lancet (London, England)|June 1, 2022
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trialsSilvio Danese, Séverine Vermeire, Wen Zhou, et al.
Gastroenterology|April 12, 2022
Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal SurgeryBenjamin L Cohen, Phillip Fleshner, Sunanda V Kane, et al.
The American Journal of Gastroenterology|January 14, 2022
Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel DiseasesMichael D Kappelman, Kimberly N Weaver, Xian Zhang, et al.
Alimentary Pharmacology & Therapeutics|November 10, 2015
Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammationA J F Coimbra, J Rimola, S O'Byrne, et al.
Journal of Pediatric Gastroenterology and Nutrition|February 15, 2024
Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel diseaseArthur J Kastl, Kimberly N Weaver, Xian Zhang, et al.
Pageof 29